BridgeBio Refocuses on Late-Stage Assets, Trims Pipeline to Sharpen Commercial Focus
Key Insights
BridgeBio is prioritizing late-stage assets like acoramidis for transthyretin amyloid cardiomyopathy (search) (ATTR-CM (search)) and infigratinib for achondroplasia (search), deemed crucial for commercial success.
The company discontinued its BBP-631 gene therapy program for congenital adrenal hyperplasia (search) (CAH (search)) after disappointing Phase 1/2 results, seeking partnerships for further development.
BridgeBio spun out its KRAS-focused oncology portfolio and early-stage assets for tuberous sclerosis complex (search) into new companies to enhance efficiency.
BridgeBio is strategically streamlining its pipeline to concentrate on late-stage assets with high commercial potential. This shift involves spinning out early-stage programs and discontinuing others to focus resources on key drugs like acoramidis for transthyretin amyloid cardiomyopathy (search) (ATTR-CM (search)) and infigratinib for achondroplasia (search).
Pipeline Prioritization
Neil Kumar, BridgeBio's CEO, emphasized the need to demonstrate commercialization capabilities alongside R&D prowess. The company has adopted a hub-and-spoke model, spinning out its KRAS-focused cancer portfolio into BridgeBio Oncology Therapeutics (search) with $200 million in funding. Additionally, GondolaBio (search) was launched to advance early-stage assets for tuberous sclerosis complex (search), erythropoietic protoporphyria (search), and alpha-A1 antitrypsin deficiency (search).
However, not all programs have made the cut. BridgeBio recently halted development of its gene therapy candidate BBP-631 for congenital adrenal hyperplasia (search) (CAH (search)) after Phase 1/2 data failed to show transformative results. "The data we generated did not suggest that our efforts would result in a meaningful step forward for patients," Kumar stated, indicating the company will seek a partnership to continue BBP-631 development.
Key Assets and Market Competition
With two approved products—Nulibry for molybdenum cofactor deficiency type A (search) and Truseltiq (infigratinib) for cholangiocarcinoma (search)—BridgeBio is now focused on four late-stage assets. Acoramidis, a transthyretin stabilizer for ATTR-CM (search), has a PDUFA date of November 29. If approved, it will compete with Pfizer's tafamidis (Vyndaqel and Vyndamax).
Kostas Biliouris, director of biotech equity research at BMO Capital Markets, noted that acoramidis may be "incrementally better" than tafamidis but requires twice-daily dosing, potentially limiting uptake. Furthermore, while tafamidis has demonstrated a reduction in mortality risk, acoramidis did not show a statistically significant effect on this measure. A BMO Capital Markets survey indicated that 50% of physicians believe the efficacy of acoramidis and tafamidis is similar, while 40% view acoramidis as incrementally better.
Achondroplasia and Future Prospects
Infigratinib is another key asset in BridgeBio's pipeline, targeting achondroplasia (search). The company anticipates a readout for infigratinib in late 2025. This drug will compete with BioMarin's Voxzogo. "It needs to be at least as good, if not better, than its main competitor," Biliouris stated, emphasizing the importance of a strong safety profile in pediatric patients.
BridgeBio's success hinges on securing FDA approval for acoramidis and meeting sales expectations. Biliouris estimates 2025 U.S. sales expectations for acoramidis to be around $165 million. The company's ability to beat this number will be crucial for its stock performance and overall narrative.